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The ABSORB bioresorbable vascular scaffold (BVS) is associated with greater 
neointimal proliferation and thrombotic rate than metal stent. The role of 
inflammatory biomarkers on neointimal proliferation has not been studied in the 
setting of BVS implantation. 
Methods 
Thirty patients had arterial blood sampling before elective PCI with the ABSORB 
BVS and at 9 month follow up. Plasma levels of IL-6, soluble CD40 ligand 
(sCD40L), monocyte chemotactic protein-1 (MCP-1) and CRP were measured using 
ELISA. Baseline and follow up levels were compared for each biomarker. Optical 
frequency domain imaging (OFDI) was performed at follow up and the neointimal 
burden was calculated as the ratio of neointimal area to scaffold area. The levels of 
inflammatory mediators were correlated with neointimal burden.  
Results 
There was no significant increase in the levels of biomarkers from baseline to follow 
up. Median CRP levels changed from 1.1 [Interquartile range (IQR): 0.5-2.5] to 2.2 
(IQR: 0.5-3.5) μg/ml, IL-6 from 1.0 (IQR: 0.6-1.4) to 1.0 (95% CI: 0.6-1.4) pg/ml, 
MCP-1 from 120.4 (IQR: 86.0-153.4) to 102.0 (IQR: 70.3-148.1) pg/ml and sCD40L 
from 108.3 (IQR: 74.1-173.7) to 112.0 (IQR: 71.0-225.9) pg/ml. The average 
neointimal burden in the cohort was 18% (±6). Baseline, follow up and change in 
plasma levels of inflammatory markers between these two time points did not 
correlate with neointimal burden. 
Conclusion 
Elective PCI with the ABSORB BVS does not provoke a chronic inflammatory 
response. The degree of neointimal proliferation after elective implantation of the 
ABSORB BVS is independent of the pre-exisiting inflammatory environment.  
  
CONDENSED ABSTRACT 
Elective PCI with the ABSORB BVS does not increase plasma levels of 
inflammatory biomarkers and therefore does not appear to cause persistent 
inflammation at medium term 
The neointimal response after elective implantation of the ABSORB BVS is 
independent of the baseline inflammatory environment.  
Thrombotic predisposition at baseline may play a role in the development of 




Randomised controlled trials and registry data have shown that the ABSORB 
bioresorbable vascular scaffold (BVS) is associated with a higher rate of thrombosis 
and late luminal loss(1, 2). Some of the contributory factors such as malapposition, 
late scaffold dismantling and underdeployment(3) have been identified but the 
influence of inflammation on the restenotic/thrombotic response has not been 
investigated. It is known that metal stents can induce chronic inflammation causing a 
potent neointimal response and a high rate of in-stent restenosis (ISR)(4). 
Histopathological analyses of restenotic tissue have shown a higher preponderance of 
inflammatory cells and fibrinoid tissue indicating an incomplete healing response(5). 
Biological factors responsible for this phenomenon include hypersensitivity reactions 
either to the metallic platform or to the polymer jacket and resistance to the anti-
proliferative drug(6, 7). In contrast, healthy porcine coronary arteries treated with the 
ABSORB BVS have shown a relatively benign vessel response compared to first 
generation drug eluting stents(8). Whether the lower levels of inflammation seen in 
these pre-clinical studies can be extrapolated to diseased human arteries is unknown.  
The inflammatory response after PCI is influenced not only by the vascular injury 
induced by the procedure but also by the pre-existing inflammatory environment. In 
clinical settings, the baseline inflammatory status has been assessed with a wide 
variety of markers including CRP, IL-6, MCP-1 and sCD40L. Patients with high pre-
interventional inflammatory activation seem to be at a greater risk of ISR(9-13). So 
far no study has investigated the effect of pre-procedural inflammatory state on 
subsequent neointimal growth after treatment with BVS. 
Methods 
Study design and population 
The study population consisted of 30 patients who had elective PCI with the 
ABSORB BVS for bifurcation disease. The inclusion criteria was the presence of 
‘false’ bifurcation disease (Medina type 1,1,0 or 1,0,0 or 0,1,0) with >70% stenosis in 
the main vessel and a side branch diameter >2mm on visual assessment. Major 
exclusion criteria were acute presentation either with unstable angina or acute 
coronary syndrome, bifurcation disease involving the left main stem and chronic total 
occlusion of either the main vessel or side branch. All patients were recruited from a 
single centre between February 2015 and July 2016. As part of the research protocol, 
all patients had peripheral arterial blood sampling before PCI (baseline) and 9 months 
after the procedure (follow up). Informed consent was obtained from all participants. 
Patients underwent optical frequency domain imaging (OFDI) post BVS implantation 
and at follow up. The clinical investigational plan, consent form and all amendments 
to these study documents were reviewed and approved by the South East Coast 
(Brighton and Sussex) Research Ethics Committee. 
Biochemical analysis 
Two sets of 10 ml blood samples were taken from the arterial sheath from each 
patient, first before scaffold implantation and again at 9 months after implantation. 
Blood was collected in EDTA-tubes (BD Vacutainers, purple cap) and centrifuged at 
1,500 rpm for 10 min.  The resulting plasma was collected and aliquoted into 5 
samples of 500 µl each. All samples were processed and frozen within 3 hours of 
collection. Samples were stored at -80˚C at the local hospital. These were transferred 
on dry ice to the laboratory for analysis. Plasma levels of inflammatory markers were 
measured by enzyme-linked immunosorbent assay (ELISA) using commercially 
available assay kits from DRG Diagnostics, Marburg, Germany (high-sensitivity 
CRP) and Bio-Techne, Minneapolis, USA (high-sensitivity IL-6, sCD40L and MCP-
1).  
OFDI acquisition and analysis 
OFDI imaging was performed using the FastView catheter R and the Lunawave 
coronary imaging console (Terumo Corporation, Tokyo, Japan). The OFDI catheter 
was carefully advanced over a guidewire beyond the target area. While contrast was 
continuously injected at a rate of 4ml/s, OFDI images of the main vessel were 
acquired at a rate of 160 frames/second with a pullback speed of 20mm/s. 
OFDI analysis was performed offline using software provided by Terumo (Terumo 
Corporation, Toyko, Japan). Quantitative measurements were performed at 1mm 
intervals starting from the first image where at the scaffold was visible in at least 3 
quadrants. In each slice, the abluminal scaffold area, total strut area and luminal area 
were measured. Neointimal burden was calculated as the percentage of neointimal 
area to scaffold area as shown below(14). 
𝑁𝑒𝑜𝑖𝑛𝑡𝑖𝑚𝑎𝑙 𝑏𝑢𝑟𝑑𝑒𝑛 =  (𝑁𝑒𝑜𝑖𝑛𝑡𝑖𝑚𝑎𝑙 𝑎𝑟𝑒𝑎/ 𝑆𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑎𝑟𝑒𝑎 )𝑥100 % 
Statistical analysis 
Continuous variables are presented as mean (± standard deviation) if normally 
distributed and median (interquartile range [IQR]) when not normally distributed. 
Discrete data is presented as percentage (count). Test for normality was performed 
with the Shapiro-Wilk test. The distribution of inflammatory biomarker levels was 
non-normal and thus comparison between baseline and follow up levels were made 
using the Wilcoxon signed rank test. Correlation between levels of inflammatory 
markers and neointimal burden was made using the Spearman rank correlation 
coefficient. The level of statistical significance for hypothesis testing was p<0.05. All 
statistical calculations were performed using SPSS software (version 24, SPSS Inc., 
Chicago, Illinois).   
Results 
Population characteristics 
Table 1 summarises the patient and procedural characteristics at baseline. Twenty 
three patients (77%) were male and mean age was 62.8 years. All patients had stable 
coronary disease. None of the patients had a pre-existing inflammatory condition, 
renal or liver dysfunction. Procedural success was 100%. Mean follow up period was 
313 (± 50) days.  
Imaging results at 9 months  
There were no cases of either binary restenosis or thrombosis. All stented vessels and 
side branches were widely patent. Vascular response was fairly benign with an 
average neointimal burden of 18 (± 6) %. Mean in-scaffold luminal diameter reduced 
from 2.89 (± 0.35) mm to 2.70 (± 0.39)mm (p=0.0001).  
Relationship between baseline and follow up levels of inflammatory 
markers 
Table 2 compares the baseline and follow up levels of each marker. None of the 
inflammatory markers showed a significant change in plasma level from baseline to 
follow up.  
Relationship between inflammatory markers and neointimal growth 
Table 3 summarises the Spearman correlation between each marker and neointimal 
burden on follow up OFDI. We investigated levels at baseline, follow up as well as 
the difference in levels between the two time points (∆= follow up levels – baseline 
levels). None of these parameters showed a significant association with the degree of 
neointimal growth at 9 months. It is worth mentioning one case where the patient had 
a significantly elevated sCD40L baseline level of 2421 pg/ml compared to the cohort 
median of 108 pg/ml. The patient’s clinical and procedural characteristics were not 
significantly different from those in the group. Interestingly, there was a large amount 
of intracoronary thrombus evident on OFDI shortly after BVS deployment despite 
pre-procedural treatment with DAPT (Figure 1). By 9 months, the sCD40L level had 
reduced to 71 pg/ml. OFDI imaging at that time point did not demonstrate persistent 
thrombus or an excessive hyperplastic response (neointimal burden 19%) 
Discussion 
Our study is the first to look at the influence of serum markers of inflammation in the 
context of PCI with the ABSORB BVS. The findings of our study can be summarised 
as such: 1) BVS implantation in an elective setting does not cause persistent 
inflammation at 9 months as assessed by serum inflammatory markers; and 2) the 
extent of neointimal tissue growth is independent of the inflammatory status at 
baseline and follow up.  
BVS implantation in an elective setting is not associated with persistent inflammation 
at 9 months  
Elective stenting initiates a complex cascade of physiological processes aimed at 
repairing the vessel. This local inflammatory process can be assessed using indices in 
the peripheral blood (15, 16). Persistence of the inflammatory process after stent 
implantation changes the physiological reparative response to a pathological one. The 
underlying inflammatory environment is a strong predictor of in-stent restenosis and 
stent thrombosis (17). In the clinical setting, this chronic inflammatory response 
causes elevated levels of systemic biomarkers, which can be used as a surrogate 
marker for the underlying inflammatory status (18).  
Based on our study, the polymer and its degradation products do not seem to evoke a 
systemic inflammatory response at medium term after the ABSORB BVS is 
implanted in an elective setting. Despite extensive published literature on the 
ABSORB BVS, the inflammatory response in humans is still poorly understood. 
Chronic low grade inflammation induced by either the polymer or its degradation 
products has been postulated as one possible cause for the high thrombotic rate(3). 
However both PLLA(19) and PDLLA(20) polymers have been used in the human 
coronary artery without major safety concerns. The final degradation products of the 
scaffold are D-lactic acid and L-lactic acid both of which naturally occur in the body. 
The amount of these products dispersed into the body as a result of scaffold 
disintegration is far below the normal reference levels in the body (21). It does not 
appear that the intermediate oligomers elicit a toxic tissue response either, at least in 
animal studies. In a swine model implanted with BVS, the percentage of struts with 
giant cells and granulomas decreases progressively over 24 months(8) and in a swine 
model PDLLA-based BRS induce inflammation with a peak at 6 months and 
decreasing thereafter(22). 
However inflammation may play a more prominent role in the more advanced stages 
of bioresorption. While the vascular response in porcine arteries is relatively benign, 
the inflammation score is at its peak between 12 and 18mths(23). This timing 
coincides with the highest rate of mass loss and formation of degradation products.  
Our findings are supported by the comparable incidence of binary restenosis at 1 year 
between BVS and Xience DES seen in ABSORB China(24) and Japan(25).  
The extent of neointimal tissue growth at 9 months is independent of the inflammatory 
status at baseline and follow up 
The biologic response to the ABSORB BVS is probably closer to that following PCI 
with DES than with BMS. While the predictive role of preprocedural inflammation in 
the development of BMS restenosis is well established, its significance in patients 
receiving DES is less clear. Several studies have failed to demonstrate an association 
between neointimal hyperplasia and either pre or post interventional biomarker levels 
in DES restenosis(10, 26, 27). The release of potent antiproliferative agents in DES 
alters the biological response to vessel injury. Limus analogues have anti-
inflammatory properties in addition to their inhibitory effect on the cell cycle. In 
particular, everolimus has been found to inhibit neutrophil activation, mitigate pro-
inflammatory TNF related pathways and promote the release on the anti-
inflammatory cytokines(28, 29). In addition, inhibition of the mTOR pathway in 
platelets prevents platelet activation and aggregation. This suppressive effect on 
inflammation may explain the lack of correlation we observed between baseline 
inflammatory status and neointimal growth. 
We also did not observe any association between follow up levels of inflammatory 
markers and intensity of neointimal response. It is possible that the excessive 
hyperplastic response seen in restenosis is effected through mechanisms other than 
inflammation. In contrast to restenosis in BMS, a heterogeneous tissue composition is 
observed in most cases of BVS restenosis. In particular, restenotic lesions that occur 
more than 6 month after implantation show signs suggestive of 
neoatherosclerosis(30). Such systemic processes may play a more important role than 
locally induced inflammation in the pathology of BVS restenosis.  
Finally, the case of very high pre-procedural sCD40L level deserves special mention. 
sCD40L not only plays a role in inflammation but also in platelet activation after 
plaque rupture, as the CD40/CD40L complex increases the expression of tissue factor 
while thrombomodulin expression is reduced thus creating a procoagulant state(31). 
Studies using IL-6 and other markers as surrogates of inflammation have compared 
levels of sCD40L in both healthy subjects and cardiac patients(32). sCD40L levels 
appears to be more a marker of platelet activation than inflammation in patients with 
coronary artery disease. The large thrombotic burden evident on OFDI in conjunction 
with the very high pre-procedural sCD40L suggest that pre-existing thrombotic 
propensity may be an important factor in the development of scaffold thrombosis. The 
identification of such individuals may be key to the challenging issue of in-scaffold 
thrombosis. The choice of appropriate biomarkers of platelet activation for risk 
stratification warrants further investigation. 
Limitations 
The main limitation of our study is its small sample size. This was a single centre 
study and our data may not be applicable to all patients. Baseline inflammatory 
marker levels were low in our group and our results may not be applicable in the 
higher inflammatory environment of acute coronary syndromes. None of the patients 
in our cohort had extensive neointimal proliferation on OFDI or angiographic in-stent 
restenosis. It is possible that inflammatory markers only show discriminatory power 
in patients with large neointimal burden. Furthermore, our study design was limited to 
9 months with an OFDI endpoint. Thus we cannot comment on the role of 
inflammation in the advanced stages of the resorption process. Very late ISR and 
thrombosis may progress through different pathological mechanisms that would not 
have been identified in our study.  
Conclusions 
Elective implantation of the ABSORB BVS does not elicit persistent inflammation 
within the coronary artery at medium term. The neointimal response after scaffold 
implantation is independent of the underlying inflammatory environment before 
scaffold implantation and at follow up. Thrombotic predisposition at baseline may 
play a part in the development of subsequent scaffold thrombosis. Future studies are 
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Figure 1: OFDI image demonstrating multiple thrombi after BVS deployment. The 
patient had a significantly elevated baseline level of sCD40L (2421 pg/ml) compared to 
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Table 1: Clinical and procedural characteristics of study cohort 
Patient characteristics 
 Age 62.8 (± 10.4) 
Gender (male)  76.7 (23) 
BMI 28.3 (± 5.1) 
Hypertension 46.7 (14) 
Hyperlipidaemia 14 (46.7) 
Current smoker 5 (16.7) 
Diabetes Mellitus 5 (16.7) 
Family History of IHD 11 (36.7) 
Creatinine (μmol/l)  84.7(± 15.3) 
Previous MI 33.3 (10) 
Previous PCI 36.7 (11) 
Previous CABG 0 
Previous Stroke/TIA 3.3 (1) 
PVD 0 
Inflammatory condition 0 
Stable angina 20 (66.7) 
Silent ischaemia 10 (33.3) 
ACS 0 
Lesion characteristics 
 B2/C lesion 20 (66.7) 
Mod/severe calcification 10 (33.3) 
Procedural characteristics  
 BVS Diameter (mm) 3.0 (± 0.3) 
BVS Length (mm) 23.9 (± 6.9) 
Number of BVS 1.1 (± 0.3) 
Procedural success 100 (30) 




Table 2: Inflammatory marker levels were measured at baseline (before scaffold 
implantation) and at follow-up (9 months after scaffold implantation) in 30 patients, and  
the median and interquartile range is reported. The changes between baseline and 
follow-up inflammatory markers levels were analysed by Wilcoxon signed-rank test and 
the p value is reported. 
 
Baseline Follow-up p value 
        
CRP (μg/ml) 
   median (IQ range) 1.1 (0.5-2.5) 2.2 (0.5-3.5) 0.082 
    IL-6 (pg/ml)
   median (IQ range) 1.0 (0.6-1.4) 1.0 (0.60-1.4) 0.975 
    MCP-1 (pg/ml) 
   median (IQ range) 120.4 (86.0-153.4) 102.0 (70.3-148.1) 0.061 
    sCD40L (pg/ml) 
   median (IQ range) 108.3 (74.1-173.7) 112.0 (71.0-225.9) 0.734 
        
 
  
Table 3:  Correlation between levels of inflammatory markers (baseline, follow up and 
the difference between the two denoted as Δ) and neointimal burden quantified on OFDI 
was made using the Spearman rank correlation coefficient.  
Marker 
Spearman Correlation 
coefficient p value 
CRP baseline 0.03 0.89 
CRP fup -0.05 0.81 
∆CRP -0.11 0.57 
   IL-6 baseline 0.22 0.25 
IL-6 fup 0.25 0.18 
∆IL-6 0.06 0.74 
   MCP-1
baseline -0.16 0.4 
MCP-1 fup 0.05 0.8 
∆MCP-1 0.2 0.28 
   sCD40L 
baseline -0.13 0.51 
sCD40L fup 0.18 0.35 
∆sCD40L 0.22 0.25 
 
 
 
 
